Breast cancer learning health system: Patient information from a data and analytics platform characterizes care provided

IF 2.6 Q2 HEALTH POLICY & SERVICES
Mark N. Levine, Joel Kemppainen, Morgan Rosenberg, Christopher Pettengell, Jessica Bogach, Tim Whelan, Ashirbani Saha, Jonathan Ranisau, Jeremy Petch
{"title":"Breast cancer learning health system: Patient information from a data and analytics platform characterizes care provided","authors":"Mark N. Levine,&nbsp;Joel Kemppainen,&nbsp;Morgan Rosenberg,&nbsp;Christopher Pettengell,&nbsp;Jessica Bogach,&nbsp;Tim Whelan,&nbsp;Ashirbani Saha,&nbsp;Jonathan Ranisau,&nbsp;Jeremy Petch","doi":"10.1002/lrh2.10409","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>In a learning health system (LHS), data gathered from clinical practice informs care and scientific investigation. To demonstrate how a novel data and analytics platform can enable an LHS at a regional cancer center by characterizing the care provided to breast cancer patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Socioeconomic information, tumor characteristics, treatments and outcomes were extracted from the platform and combined to characterize the patient population and their clinical course. Oncologists were asked to identify examples where clinical practice guidelines (CPGs) or policy changes had varying impacts on practice. These constructs were evaluated by extracting the corresponding data.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Breast cancer patients (5768) seen at the Juravinski Cancer Centre between January 2014 and June 2022 were included. The average age was 62.5 years. The commonest histology was invasive ductal carcinoma (74.6%); 77% were estrogen receptor-positive and 15.5% were HER2 Neu positive. Breast-conserving surgery (BCS) occurred in 56%. For the 4294 patients who received systemic therapy, the initial indications were adjuvant (3096), neoadjuvant (828) and palliative (370). Metastases occurred in 531 patients and 495 patients died. Lowest-income patients had a higher mortality rate. For the adoption of CPGs, the uptake for adjuvant bisphosphonate was very low, 8% as predicted, compared to 64% for pertuzumab, a HER2 targeted agent and 40.2% for CD4/6 inhibitors in metastases. During COVID-19, the provincial cancer agency issued a policy to shorten the duration of radiation after BCS. There was a significant reduction in the average number of fractions to the breast by five fractions.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our platform characterized care and the clinical course of breast cancer patients. Practice changes in response to regulatory developments and policy changes were measured. Establishing a data platform is important for an LHS. The next step is for the data to feedback and change practice, that is, close the loop.</p>\n </section>\n </div>","PeriodicalId":43916,"journal":{"name":"Learning Health Systems","volume":"8 3","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lrh2.10409","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Learning Health Systems","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/lrh2.10409","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

In a learning health system (LHS), data gathered from clinical practice informs care and scientific investigation. To demonstrate how a novel data and analytics platform can enable an LHS at a regional cancer center by characterizing the care provided to breast cancer patients.

Methods

Socioeconomic information, tumor characteristics, treatments and outcomes were extracted from the platform and combined to characterize the patient population and their clinical course. Oncologists were asked to identify examples where clinical practice guidelines (CPGs) or policy changes had varying impacts on practice. These constructs were evaluated by extracting the corresponding data.

Results

Breast cancer patients (5768) seen at the Juravinski Cancer Centre between January 2014 and June 2022 were included. The average age was 62.5 years. The commonest histology was invasive ductal carcinoma (74.6%); 77% were estrogen receptor-positive and 15.5% were HER2 Neu positive. Breast-conserving surgery (BCS) occurred in 56%. For the 4294 patients who received systemic therapy, the initial indications were adjuvant (3096), neoadjuvant (828) and palliative (370). Metastases occurred in 531 patients and 495 patients died. Lowest-income patients had a higher mortality rate. For the adoption of CPGs, the uptake for adjuvant bisphosphonate was very low, 8% as predicted, compared to 64% for pertuzumab, a HER2 targeted agent and 40.2% for CD4/6 inhibitors in metastases. During COVID-19, the provincial cancer agency issued a policy to shorten the duration of radiation after BCS. There was a significant reduction in the average number of fractions to the breast by five fractions.

Conclusion

Our platform characterized care and the clinical course of breast cancer patients. Practice changes in response to regulatory developments and policy changes were measured. Establishing a data platform is important for an LHS. The next step is for the data to feedback and change practice, that is, close the loop.

Abstract Image

乳腺癌学习保健系统:来自数据和分析平台的患者信息描述了所提供护理的特点
在学习型医疗系统(LHS)中,从临床实践中收集的数据可为护理和科学研究提供依据。从平台中提取社会经济信息、肿瘤特征、治疗方法和结果,并将其结合起来,以描述患者群体及其临床过程。肿瘤学家被要求找出临床实践指南(CPG)或政策变化对实践产生不同影响的实例。2014年1月至2022年6月期间在汝拉温斯基癌症中心就诊的乳腺癌患者(5768人)被纳入其中。平均年龄为 62.5 岁。最常见的组织学类型为浸润性导管癌(74.6%);77%为雌激素受体阳性,15.5%为HER2 Neu阳性。56%的患者接受了保乳手术(BCS)。在接受系统治疗的 4294 例患者中,最初的适应症为辅助治疗(3096 例)、新辅助治疗(828 例)和姑息治疗(370 例)。531名患者出现转移,495名患者死亡。低收入患者的死亡率较高。在采用 CPGs 方面,辅助治疗双膦酸盐的采用率非常低,仅为预测的 8%,而 HER2 靶向药物百妥珠单抗的采用率为 64%,CD4/6 抑制剂治疗转移瘤的采用率为 40.2%。在 COVID-19 期间,省癌症机构发布了一项政策,缩短了 BCS 后的放疗时间。我们的平台描述了乳腺癌患者的护理和临床过程。我们的平台描述了乳腺癌患者的护理和临床过程,并测量了根据监管发展和政策变化而发生的实践变化。建立数据平台对长期保健服务非常重要。下一步是让数据反馈并改变实践,即实现闭环。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Learning Health Systems
Learning Health Systems HEALTH POLICY & SERVICES-
CiteScore
5.60
自引率
22.60%
发文量
55
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信